Mcdonald Capital Investors Has Increased Its Ecolab (ECL) Position; Cypress Asset Management Increased Its Abbott Labs (ABT) Stake

February 18, 2018 - By Dolores Ford

Mcdonald Capital Investors Inc increased its stake in Ecolab Inc (ECL) by 1.15% based on its latest 2017Q3 regulatory filing with the SEC. Mcdonald Capital Investors Inc bought 10,153 shares as the company’s stock rose 2.53% with the market. The hedge fund held 895,708 shares of the package goods and cosmetics company at the end of 2017Q3, valued at $115.20M, up from 885,555 at the end of the previous reported quarter. Mcdonald Capital Investors Inc who had been investing in Ecolab Inc for a number of months, seems to be bullish on the $37.99 billion market cap company. The stock decreased 0.21% or $0.28 during the last trading session, reaching $131.49. About 1.30M shares traded or 2.74% up from the average. Ecolab Inc. (NYSE:ECL) has risen 9.41% since February 18, 2017 and is uptrending. It has underperformed by 7.29% the S&P500.

Cypress Asset Management Inc increased its stake in Abbott Labs (ABT) by 17.18% based on its latest 2017Q3 regulatory filing with the SEC. Cypress Asset Management Inc bought 6,870 shares as the company’s stock declined 3.42% while stock markets rallied. The institutional investor held 46,863 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $2.50 million, up from 39,993 at the end of the previous reported quarter. Cypress Asset Management Inc who had been investing in Abbott Labs for a number of months, seems to be bullish on the $104.73 billion market cap company. The stock increased 1.13% or $0.67 during the last trading session, reaching $60.17. About 7.85M shares traded or 12.40% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since February 18, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Since August 16, 2017, it had 0 insider buys, and 7 insider sales for $31.71 million activity. 227,412 Abbott Laboratories (NYSE:ABT) shares with value of $14.27M were sold by Fussell Stephen R. On Tuesday, January 30 the insider Ford Robert B sold $2.69M. Salvadori Daniel Gesua Sive sold 96,603 shares worth $5.43 million. Blaser Brian J also sold $1.73 million worth of Abbott Laboratories (NYSE:ABT) shares.

Cypress Asset Management Inc, which manages about $464.60 million US Long portfolio, decreased its stake in Jpmorgan Chase & Co (NYSE:JPM) by 13,899 shares to 131,761 shares, valued at $12.58M in 2017Q3, according to the filing. It also reduced its holding in Occidental Pete Corp Del (NYSE:OXY) by 9,225 shares in the quarter, leaving it with 9,833 shares, and cut its stake in Goldman Sachs Group Inc (NYSE:GS).

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It dropped, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. 90,729 are owned by Meag Munich Ergo Kapitalanlagegesellschaft Mbh. Gamco Et Al stated it has 66,728 shares or 0.02% of all its holdings. Westpac Bk reported 517,912 shares. Warren Averett Asset Mgmt Limited Com invested in 13,092 shares or 0.15% of the stock. Steinberg Asset Mgmt Ltd Liability Company reported 1.64% of its portfolio in Abbott Laboratories (NYSE:ABT). 353,298 are held by Lpl Fincl Lc. Atwood Palmer Incorporated invested in 5,700 shares. Carderock Cap Mgmt Incorporated has invested 0.2% in Abbott Laboratories (NYSE:ABT). Advsrs Asset Mngmt accumulated 0.13% or 149,847 shares. Frontier Mgmt Company owns 8,271 shares. Ferguson Wellman Mgmt accumulated 54,977 shares. Everett Harris & Comm Ca holds 2.62% or 1.64 million shares. North Management holds 465,141 shares. Cedar Hill Assoc Ltd Liability Com owns 19,465 shares for 0.18% of their portfolio. Gw Henssler Assoc holds 1.36% or 254,889 shares.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. BMO Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Wednesday, January 24 with “Buy” rating. Wells Fargo maintained the shares of ABT in report on Thursday, August 27 with “Buy” rating. Cowen & Co maintained the stock with “Buy” rating in Friday, September 22 report. RBC Capital Markets maintained the stock with “Buy” rating in Monday, June 26 report. The rating was downgraded by Northland Capital to “Hold” on Thursday, September 28. Jefferies maintained Abbott Laboratories (NYSE:ABT) rating on Tuesday, October 10. Jefferies has “Buy” rating and $58.0 target. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, July 20 report. On Thursday, July 14 the stock rating was maintained by Jefferies with “Buy”. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Friday, September 22 by Stifel Nicolaus. On Thursday, September 28 the stock rating was maintained by Wells Fargo with “Buy”.

Since September 14, 2017, it had 0 insider buys, and 1 sale for $966,233 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>